Myopia (near-sightedness) has become a significant public health concern, as its prevalence continues to increase in the United States and around the world. Further, myopia is also linked to potentially blinding ocular disease. Growing evidence from a number of studies links myopia with an increased risk of glaucoma, a leading cause of irreversible blindness. Eyes with primary open angle glaucoma typically exhibit high intraocular pressure (IOP) and altered diurnal IOP rhythms. The structural organization of the lamina cribrosa (LC) of the optic nerve head may also render eyes more vulnerable to nerve fiber damage, the origin of vision loss in glaucoma. One or more of these factors may also contribute to the increased risk of glaucoma in myopic eyes.
IOP could play a role in normal ocular “growth” (enlargement), by exerting a stretching influence on the scleral wall of the eye. During myopia development and progression, scleral remodelling is upregulated, rendering it more susceptible to the stretching influences of IOP, with eye enlargement accelerating as a consequence. The converse that ocular elongation can be slowed by decreasing IOP and so the tension experienced by the sclera was tested in a set of experiments using a topical ocular hypotensive drug, specifically latanoprost. Its effects on both normal and “myopic” ocular growth in guinea pigs undergoing monocular form deprivation were examined, and treatment-induced ultrastructural changes in the sclera were quantified.
With advances in high-resolution imaging and electron microscopy, we were able to characterize the effects of the above ocular hypotensive drug on the microarchitectural changes in the sclera and optic nerve head, including the LC.
Our results demonstrate that daily topical latanoprost is effective in both lowering IOP and slowing myopia progression in myopic guinea pig eyes. It also seems to protect the myopic scleral remodelling. These findings will open the opportunities to explore lowering IOP as a myopia control treatment option that may also reduce any future risk of glaucoma in myopic children.
|Advisor:||Wildsoet, Christine F.|
|Commitee:||Flanagan, John G., Jewell, Nicholas P.|
|School:||University of California, Berkeley|
|School Location:||United States -- California|
|Source:||DAI-B 81/3(E), Dissertation Abstracts International|
|Keywords:||Intraocular pressure, Latanoprost, Myopia|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be